{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34210679",
  "DateCompleted": {
    "Year": "2021",
    "Month": "11",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "11",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1158/1055-9965.EPI-21-0427"
    ],
    "Journal": {
      "ISSN": "1538-7755",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "7",
        "PubDate": {
          "Year": "2021",
          "Month": "Jul"
        }
      },
      "Title": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",
      "ISOAbbreviation": "Cancer Epidemiol Biomarkers Prev"
    },
    "ArticleTitle": "A Rare Cancer Opportunity.",
    "Pagination": {
      "StartPage": "1300",
      "EndPage": "1301",
      "MedlinePgn": "1300-1301"
    },
    "Abstract": {
      "AbstractText": [
        "In this issue of <i>Cancer Epidemiology, Biomarkers & Prevention</i>, Gallicchio and colleagues analyze recent rare-cancers research and suggest broad themes for accelerating progress in this important area. Whether the type of portfolio creation and portfolio management strategies that have worked for common cancers also work best for rare cancers warrants asking. This commentary argues for consideration of additional approaches. Incorporating principles and successes from large-scale network-based clinical trials and from advocacy-based research, and new ways to approach consortia, might accelerate the quantity and improve the quality of future rare-cancer research. Rare cancers significantly influence the overall cancer burden and cancer disparities. Creative community-based approaches to improve rare-cancers research should be considered.<i>See related article by Gallichio et al., p. 1305</i>."
      ],
      "CopyrightInformation": "\u00a92021 American Association for Cancer Research."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California. jlacey@coh.org."
          }
        ],
        "LastName": "Lacey",
        "ForeName": "James V",
        "Initials": "JV",
        "Suffix": "Jr"
      }
    ],
    "GrantList": [
      {
        "GrantID": "U01 CA199277",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Comment"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cancer Epidemiol Biomarkers Prev",
    "NlmUniqueID": "9200608",
    "ISSNLinking": "1055-9965"
  },
  "CommentsCorrectionsList": [
    {
      "RefSource": "Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1305-1311",
      "PMID": "33795213"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "epidemiology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    }
  ]
}